Paving the way for future PSMA inhibitors: insights from comparative preclinical evaluations of structure modifications

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15640%2F25%3A73632622" target="_blank" >RIV/61989592:15640/25:73632622 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/25:73632622
Result on the web
<a href="https://link.springer.com/article/10.1186/s41181-025-00389-w" target="_blank" >https://link.springer.com/article/10.1186/s41181-025-00389-w</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s41181-025-00389-w" target="_blank" >10.1186/s41181-025-00389-w</a>

Result language
angličtina
Original language name
Paving the way for future PSMA inhibitors: insights from comparative preclinical evaluations of structure modifications
Original language description
BackgroundProstate-specific membrane antigen (PSMA) is an established target for the imaging and treatment of prostate cancer. This study focused on the preclinical evaluation of three novel PSMA inhibitors-P15, P16, and P19-which were structurally modified compared to the clinically used PSMA-617. Two main strategies were pursued: a chemical approach following the so-called reversed synthetic strategy, and the replacement of the naphthyl-based linker moiety with an analogous diphenyl-based moiety. ...
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)